+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

  • ID: 1948434
  • Company Profile
  • October 2011
  • MP Advisors
1 of 5
Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5
- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis
Note: Product cover images may vary from those shown
4 of 5
- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll